Pharmacy Stocks and Companies in India

The largest Pharmacy stocks in India by market value are Entero Healthcare Solutions (₹8,291 crore), Medplus Health Services (₹7,265 crore) and Zota Health Care (₹4,264 crore), at prices of 6 Nov 2026.

• Entero Healthcare Solutions: ₹1,900.40 | market value ₹8,291 crore | P/E 58.0
• Medplus Health Services: ₹604.60 | market value ₹7,265 crore | P/E 34.4
• Zota Health Care: ₹1,231.10 | market value ₹4,264 crore
• Health X Platform: ₹272.55 | market value ₹867 crore
• Sastasundar Ventures: ₹275 (price from the week of 29 Mar 2026) | market value ₹874 crore | P/E 33.7

Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 6 Nov 2026; the score list below uses the weekly figures.

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 30 Oct 2026.

All 5 listed Indian Pharmacy Distribution companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Pharmacy Distribution index; NSE publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. Every figure is equal-weighted across those companies and carries its own as-of date.

1. Entero Healthcare Solutions Ltd₹7,650 cr
2. Medplus Health Services Ltd₹6,970 cr
3. Zota Health Care Ltd₹4,220 cr
4. Health X Platform Ltd₹921 cr
5. Sastasundar Ventures Ltd₹874 cr

5 Pharmacy companies in the Pharmacy Distribution industry group have a page on Sector Alpha, by market value as of 30 October 2026, and all 5 are listed below, largest first. The largest is Entero Healthcare Solutions (₹7,653 crore) and the smallest with a market value is Sastasundar Ventures.

Download all 5 Pharmacy companies (CSV)

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 20% ahead of NIFTY 500. Earnings across its companies grew 28% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 11 weeks running.

Price and the fundamentals both up. 1 of 5 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).

Ahead of NIFTY 500 on the three-month view for 11 weeks running; 2 of the 5 companies in the industry index above their 200-day average (no change from four weeks earlier); 1 of those 5 pass the momentum test (no change from four weeks earlier); earnings rising at 4 of the 5 that report earnings.

Ahead of NIFTY 500 for 11 weeks running, participation steady at 1 → 1 of 5. Earnings confirming, 4 of 5 members have higher trailing twelve-month earnings than a year ago.

Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 5 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Pharmacy Distribution has done better than the NIFTY 500 by 6.1% over the last 52 weeks. Over 13 weeks the gap is a lead of 9.2%. Entero Healthcare Solutions Ltd is the strongest against the sector itself at +27%. Readings are as of 30 October 2026.

Relative-strength score for the industry: 54.1 as of 30 October 2026 (narrowing, rising).

Pharmacy Distribution has done better than the NIFTY 500 by 6.1% over 52 weeks and by 9.2% over 13 weeks. 1 of 5 companies we track is beating the NIFTY on relative strength (how a share price has done against the index over recent months) (1 has no relative-strength reading yet), and 1 of the 2 with a long enough price history is ahead of the industry itself.

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Entero Healthcare Solutions Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 72.3% evidence confidence.

Medplus Health Services Ltd scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

Ranked last: too little evidence (1 company)

Under 60% of the evidence behind this score is available, so it ranks after every company above, whatever the score.

Entero Healthcare Solutions Ltd has the strongest one-year price move in Pharmacy Distribution at +42.5%. It also leads on relative strength against the NIFTY, at +30.4%. 2 of 5 companies we track are ahead of the index on that measure (1 has no relative-strength reading yet). Every line covers 313 weekly closes through 30 October 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Pharmacy Distribution itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

Strongest against NIFTY 500

Strongest against the sector itself

An attempted earnings recovery remains inside a long price range, with uneven company margins and no confirmed broad breakout. In the week of 5 October 2026, 66.7% of 3 Pharmacy Distribution companies were beating the Nifty 500, against 100% on 25 May 2026.

From our industry review of 10 October 2026.

2 of 4 Pharmacy Distribution companies held a results call for July to September 2026. Zota Health Care guided: Second-half addition of 400-450 stores toward full-year plan following deliberate Q2 moderation.

From the results calls for July to September 2026.

Big funds, foreign and Indian, kept their stake about the same over the last two quarters. Founders and promoters kept theirs about the same.

• Spending on new plants and equipment was ₹602 crore in the last 12 months, 3% more than a year before.
• Projects still being built grew 38% in a year.
• 1 Pharmacy Distribution call in the last quarters talked about adding capacity.

Big funds = foreign and Indian institutions, change in their share of ownership across 4 Pharmacy Distribution companies, in percentage points.

Ownership and spending as of 10 October 2026.

The next things that show whether the Pharmacy Distribution story is on course. First: Medplus's next results: own-brand mix recovery and operating-margin improvement after discount and labor-cost changes.

• Entero's delivery against its retained growth, margin and operating-cash conversion goals.
• Health X's Retailer Shakti profit goal and evidence that retailer software improves customer spending and inventory efficiency.
• Price and relative strength breaking above their existing sideways ranges.

What would change the story

A next quarterly result showing sector profit falling year on year together with a lower operating margin would break the attempted-recovery call. The latest comparable reference is profit of ₹87 crore and operating margin of 5.19%, with reporting coverage checked before comparison.

From our industry review of 10 October 2026.

Entero Healthcare Solutions Ltd has the highest Revenue among the 5 Pharmacy Distribution companies compared here, at ₹7,644 crore. Medplus Health Services Ltd is next at ₹7,587 crore. Zota Health Care Ltd has the highest Revenue growth at 68.9%, so level and change sit with different companies. 5 of 5 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Entero Healthcare Solutions Ltd is the largest at ₹7,644 crore, 0.8% ahead of Medplus Health Services Ltd. Zota Health Care Ltd's growth is 68.9% from a ₹679 crore base, with 20 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

What this means: Entero Healthcare Solutions Ltd is the size to compare against; Zota Health Care Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Entero Healthcare Solutions Ltd's growth falls below Zota Health Care Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

Medplus Health Services Ltd has the highest OPM among the 5 Pharmacy Distribution companies compared here, at 8%. Entero Healthcare Solutions Ltd is next at 5%. Sastasundar Ventures Ltd has the highest Margin change at +5.4 percentage points, so level and change sit with different companies. 5 of 5 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Medplus Health Services Ltd leads opm at 8%; Sastasundar Ventures Ltd leads margin change at +5.4 percentage points.

What this means: Medplus Health Services Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

Medplus Health Services Ltd has the highest Net profit among the 5 Pharmacy Distribution companies compared here, at ₹211 crore. Entero Healthcare Solutions Ltd is next at ₹192 crore. Health X Platform Ltd has the highest Profit growth at 82.5%, so level and change sit with different companies. Its Net profit series carries 20 reported observations across the 20-quarter window.

What the numbers say: Medplus Health Services Ltd earns the most, ₹211 crore of profit over the last 12 months, 9.9% above Entero Healthcare Solutions Ltd. Health X Platform Ltd shows 82.5% growth from a profit base of ₹26 crore net cash. A fast rate from a small base matters less than a large profit that keeps coming.

What this means: Medplus Health Services Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

Medplus Health Services Ltd has the highest ROCE among the 5 Pharmacy Distribution companies compared here, at 12.6%. Entero Healthcare Solutions Ltd is next at 10.5%. Sastasundar Ventures Ltd has the highest ROCE change at +2 percentage points, so level and change sit with different companies. 5 of 5 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Medplus Health Services Ltd leads ROCE at 12.6%, 2.1 percentage points above Entero Healthcare Solutions Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

What this means: Medplus Health Services Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

Withheld from this chart: Entero Healthcare Solutions Ltd (ENTERO): its two data sources disagree by up to 37% on reported income across 16 comparable periods, so its derived ratios are withheld; Health X Platform Ltd (HEALTHX): its two data sources disagree by up to 388% on reported income across 15 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

Medplus Health Services Ltd has the lowest PEG among the 5 Pharmacy Distribution companies compared here, at 1×. The same company also has the lowest P/E, at 33×. 1 of 5 companies report a comparable reading, the latest through Sep 2026. PEG asks what price is being paid for growth; P/E keeps that answer anchored to the actual earnings multiple.

What the numbers say: That would need today's multiple, the company's own history and steady growth to agree.

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Pharmacy Distribution companies show up on 4 of our India lists. The most are on the pharma stocks list (5 companies).

This Pharmacy Distribution comparison names 7 specific ways its own evidence can mislead, all listed below. 1 of the 5 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 2 have second-source figures left out because the two sources disagree.

Keep these limits visible

• A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
• A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
• The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
• An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
• 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
• 2 companies are missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.
• Thin comparisons: Valuation have fewer than three usable current readings.

This comparison is built from the reported filings of 5 Pharmacy Distribution companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 30 October 2026.

2 of 5 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Entero Healthcare Solutions Ltd (ENTERO): its two data sources disagree by up to 37% on reported income across 16 comparable periods, so its derived ratios are withheld; Health X Platform Ltd (HEALTHX): its two data sources disagree by up to 388% on reported income across 15 comparable periods, so its derived ratios are withheld.

These 23 answers restate the Pharmacy Distribution comparison above in question form. Every one is computed from the same 5 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 30 October 2026. Nothing here is estimated, and none of it is a recommendation.